SUPERNUS PHARMACEUTICALS
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company’s extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization, then as a U.S. subsidiary of Shire plc and, upon its acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.... The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy, ADHD and depression. In addition to its two ADHD product candidates, Supernus is developing two late stage epilepsy product candidates, SPN-538 (extended release topiramate), and Epliga® (extended release oxcarbazepine).
SUPERNUS PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2005-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.supernus.com
Total Employee:
251+
Status:
Active
Contact:
3014241385
Email Addresses:
[email protected]
Total Funding:
689.5 M USD
Technology used in webpage:
Domain Not Resolving Apple Mobile Web Clips Icon WordPress Font Awesome Mobile Non Scaleable Content HSTS IPv6 JsDelivr Cloudflare JS Google
Similar Organizations
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Exelixis
Exelixis works is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases.
Memory Pharmaceuticals
Memory Pharmaceuticals is focused on developing drug candidates for the treatment of central nervous system conditions.
Myriad Genetics
Myriad Genetics discovers, develops, and commercializing novel therapies for the treatment of cancer.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-10-11 | Adamas Pharmaceuticals | Adamas Pharmaceuticals acquired by Supernus Pharmaceuticals | 450 M USD |
| 2018-09-14 | Biscayne NeuroTherapeutics | Biscayne NeuroTherapeutics acquired by Supernus Pharmaceuticals | 185 M USD |
Investors List
UBS
UBS investment in Post-IPO Debt - Supernus Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series A - Supernus Pharmaceuticals
OrbiMed
OrbiMed investment in Series A - Supernus Pharmaceuticals
Official Site Inspections
http://www.supernus.com Semrush global rank: 3.46 M Semrush visits lastest month: 3.83 K
- Host name: ec2-3-214-152-230.compute-1.amazonaws.com
- IP address: 3.214.152.230
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Supernus Pharmaceuticals"
Leadership – Supernus
Since joining Supernus as the first commercial employee in 2010, Dr. Horich has played an integral leadership role in the build out of the organization, integration of corporate acquisitions, and successful launches of Trokendi XR ®, Oxtellar …See details»
Supernus Pharmaceuticals | Innovating CNS Treatments
Supernus, a biopharmaceutical company, develops CNS disease treatments. Transforming patient care with cutting-edge therapies and strategic partnerships.See details»
Supernus Pharmaceuticals, Inc. - LinkedIn
Supernus Pharmaceuticals, Inc. | 20,361 followers on LinkedIn. We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...See details»
Supernus Pharmaceuticals - Crunchbase Company …
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central …See details»
Management - Supernus Pharmaceuticals
The Investor Relations website contains information about Supernus Pharmaceuticals's business for stockholders, potential investors, and financial analysts.See details»
Supernus Pharmaceuticals, Inc. Management Team | Org Chart
Supernus Pharmaceuticals, Inc. employs 719 employees. The Supernus Pharmaceuticals, Inc. management team includes Jack Khattar (President and CEO), Chris March (Vice President …See details»
Supernus Pharmaceuticals - Leadership Team | The Org
The Leadership Team at Supernus Pharmaceuticals is responsible for guiding the strategic direction of the company and ensuring the successful development and commercialization of …See details»
Corporate Governance - Supernus Pharmaceuticals
The Board of Directors of Supernus Pharmaceuticals, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the …See details»
Supernus Medical Affairs – Advancing CNS Science for Healthcare ...
Explore educational resources and detailed information about Supernus Medical Affairs' therapeutic areas, innovative treatments, and product pipeline in psychiatry and neurology.See details»
Supernus Pharma - VentureRadar
"Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. …See details»
Supernus Pharmaceuticals, Inc. Information - RocketReach
Supernus Pharmaceuticals, Inc. is a Pharmaceutical Manufacturing, Pharmaceuticals, and Biotechnology company located in Rockville, Maryland with $630.2 million in revenue and 714 …See details»
Supernus Pharma to acquire Sage Therapeutics in up to $795 …
1 hour ago Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics , which makes treatments for neurological conditions, in a deal worth up to $795 …See details»
Supernus | The Wellness Village · Parkinson's Resource Organization
Supernus At Supernus, we hold a fundamental belief that our science has the potential to improve the lives of people with Parkinson’s disease (PD). Our commitment to people with Parkinson’s …See details»
Supernus Pharmaceuticals to Announce First Quarter 2025 …
ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing …See details»
Investor Relations – Supernus
The Supernus Investor Relations page offers information for stockholders, including press releases, proxy statements, financials, 10-K and 10-Q filings, events, presentations, and …See details»
Supernus Pharmaceuticals to Acquire Sage Therapeutics,
2 hours ago Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.See details»
Investor Relations - Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. and each of its subsidiaries are distinct legal entities. For example, MDD US Operations, LLC, a wholly-owned indirect subsidiary of Supernus …See details»
Investor Relations - Supernus Pharmaceuticals
May 28, 2025 The Investor Relations website contains information about Supernus Pharmaceuticals's business for stockholders, potential investors, and financial analysts.See details»
Supernus Pharmaceuticals to Acquire Sage Therapeutics, …
13 hours ago All forward-looking statements are based on information currently available to Sage and Supernus, and Sage and Supernus disclaim any obligation to update the …See details»
Supernus stock in focus as Sage agrees to buy (SAGE:NASDAQ)
1 hour ago Supernus Pharmaceuticals (SUPN) stock is set to rise as Sage Therapeutics (SAGE) agrees to buy it for up to $795M in an all-cash deal. Read more here.See details»